In contrast, differences in survival and treatment response of glioma are attributed to their genetic and histological characteristics, particularly isocitrate dehydrogenase (IDH) mutation status, 1p/19q co-deletion status and tumor grade (4). This evidence concerns the gene IDH1 and central nervous system cancer.